title: Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx.
abstract: OBJECTIVE
  We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx. The primary endpoint was clinical complete response (CR) to induction UFTVP, and secondary endpoints were long-term overall survival (OS) and survival with primary site preservation (SPP).
  
  
  RESULTS
  Between 1994 and 1997, 37 pts were included. CR to IC was 54% (95% confidence interval [CI] 43-65%). Main toxicity of UFTVP was G 3,4 neutropenia (73% of pts, 16% developed febrile neutropenia). After IC, primary site was treated with RT in 29 pts: 20 of them received RT/UFTJ (main toxicity mucositis G 3,4 70%). No pt died during treatment. Actuarial 5-year OS and SPP were 57% and 37%, respectively.
  
  
  CONCLUSIONS
  This approach has significant activity and acceptable toxicity for achieving promising long-term OS and SPP and deserves further investigation.
authors.affiliation: Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. oncrhf@humv.es
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivera
authors.forename: Maria E
authors.initials: ME
authors.lastname: Vega-Villegas
authors.forename: Marta F
authors.initials: MF
authors.lastname: López-Brea
authors.forename: Almudena
authors.initials: A
authors.lastname: García-Castaño
authors.forename: Ana
authors.initials: A
authors.lastname: de Juan
authors.forename: Antonio
authors.initials: A
authors.lastname: Collado
authors.forename: Piedad
authors.initials: P
authors.lastname: Galdós
authors.forename: Antonio
authors.initials: A
authors.lastname: Rubio
authors.forename: Adolfo
authors.initials: A
authors.lastname: del Valle
authors.forename: Julio
authors.initials: J
authors.lastname: Rama
authors.forename: Jaime
authors.initials: J
authors.lastname: Sanz-Ortiz
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D005641:Tegafur; D014498:Uracil; D014747:Vinblastine; D016190:Carboplatin; D002945:Cisplatin; D000077235:Vinorelbine